In this review we collect some recent achievements in the accurate and efficient solution of the Nonlinear Schrödinger Equation (NLSE), with the preservation of its Hamiltonian structure. This is achieved by using the energy-conserving Runge–Kutta methods named Hamiltonian Boundary Value Methods (HBVMs) after a proper space semi-discretization. The main facts about HBVMs, along with their application for solving the given problem, are here recalled and explained in detail. In particular, their use as spectral methods in time, which allows efficiently solving the problems with spectral space–time accuracy.

Luigi Barletti; Luigi Brugnano; Gianmarco Gurioli; Felice Iavernaro. Recent advances in the numerical solution of the Nonlinear Schrödinger Equation. Journal of Computational and Applied Mathematics 2024, 445 .

Luigi Barletti, Luigi Brugnano, Gianmarco Gurioli, Felice Iavernaro. Recent advances in the numerical solution of the Nonlinear Schrödinger Equation. Journal of Computational and Applied Mathematics. 2024; 445 ():.

Luigi Barletti; Luigi Brugnano; Gianmarco Gurioli; Felice Iavernaro. 2024. "Recent advances in the numerical solution of the Nonlinear Schrödinger Equation." Journal of Computational and Applied Mathematics 445, no. : .

Martino Pepe; Rocco Tritto; Maria Ludovica Naccarati; Simona Quarta; Andrea Marzullo; Marco Matteo Ciccone. Aortic valve fibroelastoma presenting with myocardial infarction with non-obstructive coronary arteries (MINOCA): A case report and review of the literature. Cardiovascular Pathology 2024, 71, 107631 .

Martino Pepe, Rocco Tritto, Maria Ludovica Naccarati, Simona Quarta, Andrea Marzullo, Marco Matteo Ciccone. Aortic valve fibroelastoma presenting with myocardial infarction with non-obstructive coronary arteries (MINOCA): A case report and review of the literature. Cardiovascular Pathology. 2024; 71 ():107631.

Martino Pepe; Rocco Tritto; Maria Ludovica Naccarati; Simona Quarta; Andrea Marzullo; Marco Matteo Ciccone. 2024. "Aortic valve fibroelastoma presenting with myocardial infarction with non-obstructive coronary arteries (MINOCA): A case report and review of the literature." Cardiovascular Pathology 71, no. : 107631.

Background. Hypersensitivity reactions to non-steroidal anti-inflammatory drugs (HR-NSAIDs) are common adverse events related to the widespread use of over-the-counter NSAIDs for the treatment of a variety of inflammatory conditions. Urticaria is the most commonly reported immediate cutaneous clinical sign of HR-NSAIDs, but it can be a manifestation of pathophysiologically different clinical entities that require different therapeutic strategies. The aim of this study is to ease the identification of the correct phenotype of HR-NSAIDs in patients reporting urticaria associated with the intake of NSAIDs and provide updated information about their diagnosis and management. Methods. The study is a narrative review conducted by collecting the most relevant and up-to-date data related to the classification, pathophysiology, severity, and prognosis of NSAID hypersensitivity reactions. PubMed and Embase scientific databases were used as search engines to select relevant articles. Results. Patients developing HR-NSAIDs can be divided into two categories: selective responders (SR), who develop reactions after the administration of a single specific NSAID due to an underlying IgE or T-cell mediated hypersensitivity mechanism, or cross-intolerant (CI), who develop reactions to more than one chemically unrelated NSAIDs due to abnormalities in the biochemical pathways related with prostaglandin metabolism, independently from an underlying immunological mechanism. Five major different categories of HR-NSAIDs have been identified: NSAIDs-exacerbated cutaneous disease (NECD), NSAIDs-induced urticaria/angioedema with/without respiratory and systemic symptoms of anaphylaxis (NIUAA), and NSAIDs-exacerbated respiratory disease (NERD), which are developed by CI patients, and single NSAIDs-induced urticaria, angioedema and/ or anaphylaxis (SNIUAA) and single NSAIDs-induced delayed hypersensitivity reactions (SNIDHR), which are developed by CI patients. In vivo and in vitro diagnostic tests have rarely been shown to be reliable in all these entities and therefore are not routinely used in clinical practice. The management in SR patients consists of strict avoidance of the culprit drug, while for cross-intolerance reactions oral tolerance tests with safe alternative drugs (e.g. weak COX-1 inhibitors or selective COX-2 inhibitors) can be performed. Conclusion. HR-NSAIDs are being observed with increasing frequency, however, the pathogenesis behind some NSAIDS-associated clinical entities is still unclear. Diagnosis is mostly based on a thorough clinical history and confirmed by a drug challenge test. Clinical management is based on strict avoidance and use of alternative tolerated medications. Overall, all therapeutic decisions depend on the correct identification of the type of reaction the patient experienced.

Andrea Miniello; Rossella Casella; Teresa Loverre; Dario Aloia; Danilo Di Bona; Eustachio Nettis. An Update on Nonsteroidal Anti-Inflammatory Drug-Induced Urticaria. Endocrine, Metabolic & Immune Disorders - Drug Targets 2024, 24, 885 -895.

Andrea Miniello, Rossella Casella, Teresa Loverre, Dario Aloia, Danilo Di Bona, Eustachio Nettis. An Update on Nonsteroidal Anti-Inflammatory Drug-Induced Urticaria. Endocrine, Metabolic & Immune Disorders - Drug Targets. 2024; 24 (8):885-895.

Andrea Miniello; Rossella Casella; Teresa Loverre; Dario Aloia; Danilo Di Bona; Eustachio Nettis. 2024. "An Update on Nonsteroidal Anti-Inflammatory Drug-Induced Urticaria." Endocrine, Metabolic & Immune Disorders - Drug Targets 24, no. 8: 885-895.